Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE

JERUSALEM--( BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced up to 7-year efficacy, safety and tolerability results from the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study of COPAXONE ®(glatiramer acetate injection) 40 mg/mL administered subcutaneously three-times-a-week for the treatment of relapsing forms of multiple sclerosis (RMS).

The study, including the open-label phase of the largest pivotal trial ever conducted for COPAXONE ®, examined the long-term effects up to seven years of early start (ES) and delayed start (DS) treatment of COPAXONE ®40 mg/mL. Results show that favorable annualized relapse and disability progression rates are observed in both patients continuing COPAXONE ®40 mg/mL and patients switching from placebo to COPAXONE ®40 mg/mL. Additionally, no new or unexpected adverse events emerged in patients receiving the treatment.